Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3390824 Target Snapshot

Lanosterol 14-alpha demethylase · SINGLE PROTEIN · Aspergillus

Back to Search Search this target Browse approvals Evidence Card
39Compounds
6Assays
2Approved Drugs
10.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Lanosterol 14-alpha demethylase shows approved-linked disease relevance led by aspergillosis. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt A0A2P2HJL8. Start with aspergillosis, then reuse UniProt A0A2P2HJL8 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with aspergillosis, then reuse UniProt A0A2P2HJL8 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
aspergillosis

Lanosterol 14-alpha demethylase shows approved-linked disease relevance led by aspergillosis. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with aspergillosis because it currently carries approved-linked support. Linked drugs include ISAVUCONAZONIUM SULFATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Lanosterol 14-alpha demethylase as ChEMBL target CHEMBL3390824, mapped to UniProt A0A2P2HJL8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Lanosterol 14-alpha demethylase
SINGLE PROTEIN · Aspergillus
As of 2026-09-14
ChEMBL target ID
CHEMBL3390824
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
A0A2P2HJL8
Sterol 14-alpha-demethylase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Lanosterol 14-alpha demethylase is the right protein anchor across sources, using UniProt A0A2P2HJL8 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why aspergillosis is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameLanosterol 14-alpha demethylase
Target TypeSINGLE PROTEIN
OrganismAspergillus
UniProtA0A2P2HJL8
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSterol 14-alpha-demethylase
UniProt AccessionA0A2P2HJL8
Component TypeProtein
Sequence Length513 aa

Sterol 14-alpha-demethylase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Lanosterol 14-alpha demethylase, mapped to UniProt A0A2P2HJL8. ChEMBL maps the protein component as Sterol 14-alpha-demethylase. Sequence length is 513 aa.

Mapped IDA0A2P2HJL8
Review nameLanosterol 14-alpha demethylase
OrganismAspergillus
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Lanosterol 14-alpha demethylase shows approved-linked disease relevance led by aspergillosis. 3 more disease programs remain visible in the same review block.

Approved-linked Approved
aspergillosis
1 linked drug · 1 direct · 1 efficacy
Linked drugISAVUCONAZONIUM SULFATE
Approved-linked Approved
mucormycosis
1 linked drug · 1 direct · 1 efficacy
Linked drugISAVUCONAZONIUM SULFATE
Late clinical Phase III
fungal infectious disease
1 linked drug · 1 direct · 1 efficacy
Linked drugISAVUCONAZONIUM SULFATE
Clinical signal Phase I
lymphoid neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugISAVUCONAZONIUM SULFATE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with aspergillosis because it currently carries approved-linked support. Linked drugs include ISAVUCONAZONIUM SULFATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseaspergillosis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
Assay Mix

Activity Type Distribution

IC501.0
KD9.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4077246 7.89 Kd 13.0 Preclinical
CHEMBL4128885 7.7 Kd 20.0 Preclinical
CHEMBL4127493 7.26 Kd 55.0 Preclinical
CHEMBL638 7.25 Kd 56.0 Approved
CHEMBL4129161 7.24 Kd 57.0 Preclinical
CHEMBL4128615 7.21 Kd 61.0 Preclinical
CHEMBL1397 6.88 Kd 131.0 Approved
CHEMBL4126063 6.88 Kd 132.0 Preclinical
CHEMBL1236677 6.69 Kd 203.0 Preclinical
CHEMBL1236677 6.6 IC50 250.0 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
0
5.5
0
6.0
4
6.5
4
7.0
2
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

POSACONAZOLE
CHEMBL1397
Approved 2005
Properties Compare Identifier
VORICONAZOLE
CHEMBL638
Approved 2002
Properties Compare Identifier
Assay Landscape

Assay Landscape

6
Total Assays
9
Tested Compounds
1
Assay Types
Binding — 6 assays, 9 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 6 9 7.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine